NEW YORK (GenomeWeb News) – SeqWright today said that it will be the exclusive genetic testing provider for Pharmagenoma's HairDx test, which evaluates a patient's responsiveness to hair-loss treatment finasteride.

Houston-based SeqWright runs a clinical lab that offers genetic testing. The firm also offers genomics services including next-generation sequencing.

SeqWright said that the test would enable patients to determine if treatment benefit outweighs the potential side effects associated with finasteride.

Terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Sponsored by

This webinar will address a range of methods for optimizing small RNA library preparation.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.